Free Shipping on All Orders $75 Or More!

Your Trusted Brand for Over 35 Years

Health Protocols

Muscular Dystrophy


Aartsma-Rus A "Overview on DMD exon skipping." Methods Mol Biol 867 (2012): 97-116.

Abu-Baker A and Rouleau GA "Oculopharyngeal muscular dystrophy: recent advances in the understanding of the molecular pathogenic mechanisms and treatment strategies." Biochim Biophys Acta 1772 (2007): 173-185.

Aloysius A, Born P, Kinali M, et al. "Swallowing difficulties in Duchenne muscular dystrophy: indications for feeding assessment and outcome of videofluroscopic swallow studies." Eur J Paediatr Neurol 12 (2008): 239-245.

Amato AA and Griggs RC "Overview of the Muscular Dystrophies." Handb Clin Neurol 101 (2011): 1-9.

Ashizawa T and Sarkar PS "Myotonic dystrophy types 1 and 2." Handb Clin Neurol 101 (2011): 193-237.

Bakker E, Jennekens F, de VIisser M, Wintzen A. Duchenne and Becker Muscular Dystrophies. Available at: Accessed 5/20/2013. 2013.

Banerjee B, Sharma U, Balasubramanian K, et al. "effect of creatine monohydrate in improving cellular energetics and muscle strength in ambulatory Duchenne Muscular Dystrophy patients: a randomized, placebo-controlled 31P MRS study." Magn Reson Imaging 28 (2010): 698-707.

Bansal D, Miyake K, Vogel SS, et al. “Defective membrane repair in dysferlin-deficient muscular dystrophy.” Nature 423 (2003): 168-172.

Barton-Davis ER, Cordier L, Shoturma D, et al. "Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice." J Clin Invest 104 (1999): 375-381.

Beytía M, Vry J, Kirschner J. “Drug treatment of Duchenne muscular dystrophy: available evidence and perspectives.” Acta Myologica 31 (2012): 4-8.

Bianchi ML, Morandi L, Andreucci E. “Low bone density and bone metabolism alterations in Duchenne muscular dystrophy: response to calcium and vitamin D treatment.” Osteoporos Int 22 (2011): 529-539.

Biggar WD, Harris VA, Eliasoph L, et al. "Long-Term Benefits of Deflazacort Treatment for Boys with Duchenne Muscular Dystrophy in Their Second Decade." Neuromuscul Disord 16 (2006): 249-255.

Boger RH "The pharmacodynamics of L-Arginine." J Nutr 137 (2007): 1650S-1655S.

Bonne G, Leturcq F, and Ben Yaou R "Emery-Dreifuss Muscular Dystrophy." NCBI Bookshelf Bookshelf ID: NBK1436 (2010).

Bonnucelli G, Sotgia F, Capozza F, et al. "Localized treatment with a novel FDA-approved proteasome inhibitor blocks the degradation of dystrophin and dystrophin-associated proteins in mdx mice." Cell Cycle 6 (2007): 1242-1248.

Boriani G, Gallina M, Merlini L, Bonne G, Toniolo D, Amati S, . . . Branzi A. Clinical relevance of atrial fibrillation/flutter, stroke, pacemaker implant, and heart failure in Emery-Dreifuss muscular dystrophy: a long-term longitudinal study. Stroke; a journal of cerebral circulation. Apr 2003;34(4):901-908.

Brais B "Oculopharyngeal Muscular Dystrophy." Handb Clin Neurol 101 (2011): 181-192.

Briguet A, Erb M, Courdier-Fruh I, et al. "Effect of calpain and proteasome inhibition on ca2+-dependent proteolysis and muscle histopathology in the mdx mouse." FASEB J 22 (2008): 4190-4200.

Brook JD, McCurrach ME, Harley HG, et al. “Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3’ end of a transcript encoding a protein kinase family member.” Cell 68 (1992): 799-808.

Bushby K, Bourke J, Bullock R, et al. "The multidisciplinary management of Duchenne Muscular Dystrophy." Current Paediatrics 15 (2005): 292-300.

Bushby K, Finkel R, Birnkrant D, et al. "Diagnosis and management of duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management." Lancet Neurol 9 (2010A): 77-93.

Bushby K, Finkel R, Birnkrant D, et al. "Diagnosis and management of Duchenne Muscular Dystrophy, part 2: implementation of multidisciplinary care." Lancet Neurol 9 (2010B): 177-189.

Buyse GM, Goemans N, van den Hauwe M, et al. “Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: Results from a 12 month, double-blind, randomized placebo-controlled trial.” Neuromuscul Disord 21 (2011): 396-405.

Call JA, Voelker KA, Wolff AV, et al. "Endurance capacity in maturing mdx mice is markedly enhanced by combined voluntary wheel running and green tea extract." J Appl Physiol 105 (2008): 923-932.

Campbell C and Jacob P "Deflazacort for the treatment of Duchenne Dystrophy: a systematic review." BMC Neurology 3 (2003): 7.

Centers for Disease Control and Prevention. Facts - Muscular Dystrophy. Accessed December 23, 2012.

Chahbouni M, Escames G, López LC, et al. “Melatonin treatment counteracts the hyperoxidative status in erythrocytes of patients suffering from Duchenne muscular dystrophy.” Clin Biochem 44 (2011): 853-858.

Chahbouni M, Escames G, Venegas C, et al. “Melatonin treatment normalizes plasma pro-inflammatory cytokines and nitrosative/oxidative stress in patients suffering from Duchenne muscular dystrophy.” J Pineal Res 48 (2010): 282-289.

Chatterjee SK and Chakravarty A "The muscular dystrophies — from genes to proteins." JAPI 51 (2003): 202-207.

Chung YL, Alexanderson H, Pipitone N, Morrison C, Dastmalchi M, Stahl-Hallengren C, . . . Scott DL. Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: Six-month, double-blind, randomized, placebo-controlled trial. Arthritis and rheumatism. May 15 2007;57(4):694-702.

Cirak S, Arechavala-Gomeza V, Guglieri M, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet. Aug 13 2011;378(9791):595-605.

Cozzoli A, Rolland JF, Capogrosso RF, Sblendorio VT, Longo V, Simonetti S, . . . De Luca A. Evaluation of potential synergistic action of a combined treatment with alpha-methyl-prednisolone and taurine on the mdx mouse model of Duchenne muscular dystrophy. Neuropathology and applied neurobiology. Apr 2011;37(3):243-256.

Darabi R, Arpke RW, Irion S, et al. "Human ES- and IPS-derived myogenic progenitors restore dystrophin and improve contractility upon transplantation in dystrophic mice." Cell Stem Cell 10 (2012): 610-619.

Davidson ZE and Truby H "A review of nutrition in Duchenne Muscular Dystrophy." J Hum Nutr Diet 22 (2009): 383-393.

Davoodi J, Markert CD, Voelker KA, et al. "Nutrition strategies to improve physical capabilities in Duchenne Muscular Dystrophy." Phys Med Rehabil Clin N Am 23 (2012): 187-199, xii-xiii.

De Luca A, Pierno S, Liantonio A, Cetrone M, Camerino C, Fraysse B, . . . Conte Camerino D. Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1. The Journal of pharmacology and experimental therapeutics. Jan 2003;304(1):453-463.

Domingo R, Satya-Murti S, Baustian H. Clinical Key. First Consult. Muscular dystrophies and related myopathies. Available at Accessed 5/23/2013. 2011.

Dorchies OM, Wagner S, and Vuadens O. "Green tea extract and its major polyphenol (-)-epigallocatechin gallate improve muscle function in a mouse model for Duchenne Muscular Dystrophy." Am J Physiol Cell Physiol 290 (2006): C616-C624.

Dubowitz V. Muscle Disorders in Childhood. 2nd ed. Philadelphia, Pa: WB Saunders;1995: 34-132.

Durelli L, Mutani R, Fassio F. The treatment of myotonia: evaluation of chronic oral taurine therapy. Neurology. May 1983;33(5):599-603.

Ekström AB, Tulinius M, Sjostrom A, et al. "Visual function in congenital and childhood myotonic dystrophy type 1." Ophthalmology 117 (2010): 976-982.

Ellis JA "Emery-Dreifuss Muscular Dystrophy at the nuclear envelope: 10 years on." Cell Mol Life Sci 63 (2006): 2702-2709.

England SB, Nicholson LVB, Johnson MA, et al. "Very mild muscular dystrophy associated with the deletion of 46% of dystrophin." Nature (1989): 180-182.

Escolar DM, Hache LP, Clemens PR, et al. "Randomized, blinded trial of weekend vs. daily prednisone in Duchenne Muscular Dystrophy." Neurology 77 (2011): 444-452.

Fairclough RJ, Bareja A, and Davies KE "Progress in therapy for Duchenne Muscular Dystrophy." Exp Physiol 96 (2011): 1101-1113.

Fiaccavento R, Carotenuto F, and Vecchini A. "An omega-3 fatty acid-enriched diet prevents skeletal muscle lesions in a hamster model of dystrophy." Am J Pathol 177 (2010): 2176-2184.

Finanger EL, Russman B, Forbes SC, et al. "Use of skeletal muscle MRI in diagnosis and monitoring disease progression in Duchenne Muscular Dystrophy." Phys Med Rehabil Clin N Am 23 (2012): 1-10, ix.

Finsterer J "Cardiopulmonary support in Duchenne Muscular Dystrophy." Lung 184 (2006): 205-215.

Finsterer J and Stollberger C "Cardiac involvement in Becker Muscular Dystrophy." Can J Cardiol 24 (2008): 786-92.

Folkers K, Simonsen R. Two successful double-blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophies. Biochimica et biophysica acta. May 24 1995;1271(1):281-286.

Gamstorp I, Gustavson KH, Hellström O, et al. “A trial of selenium and vitamin E in boys with muscular dystrophy.” J Child Neurol 1 (1986): 211-214.

Garlaschelli D, Caldarelli G, and Pietronero L. "Universal scaling relations in food webs." Nature 423 (2003): 165-168.

Gaud A, Simon JM, and Witzel T. "Prednisone reduces muscle degeneration in dystrophin-deficient Caenorhabditis elegans." Neuromuscul Disord 14 (2004): 365-370.

Gazzerro E, Assereto S, Bonetto A, et al. "Therapeutic potential of proteasome inhibition in Duchenne and Becker Muscular Dystrophies." Am J Pathol 176 (2010): 1863-1877.

GHR. Genetics Home Reference. ALDOB. Available at: Accessed 5/24/2013. 2013.

Goodman CA, Horvath D, Stathis C, Mori T, Croft K, Murphy RM, Hayes A. Taurine supplementation increases skeletal muscle force production and protects muscle function during and after high-frequency in vitro stimulation. Journal of applied physiology (Bethesda, Md. : 1985). Jul 2009;107(1):144-154.

Gordon BS, Delgado Díaz DC, and Kostek MC. “Resveratrol decreases inflammation and increases utrophin gene expression in the mdx mouse model of duchenne muscular dystrophy.” Clin Nutr. 2013 Feb;32(1):104-11. Epub 2012 Jul 12.

Griggs RC and Amato AA. “Muscular Dystrophies E-Book.” Handbook of Clinical Neurology 101 (2011).

Guglieri M and Bushby K "Recent developments in the management of Duchenne Muscular Dystrophy." Paediatrics and Child Health 21 (2011): 501-509.

Gumerson JD and Michele DE "The Dystrophin-Glycoprotein Complex in the prevention of muscle damage." J Biomed Biotechnol 2011 (2011): 210797.

Hamed SA. Drug evaluation: PTC-124--a potential treatment of cystic fibrosis and Duchenne muscular dystrophy. IDrugs. Nov 2006;9(11):783-9.; PTC Therapeutics, Inc. PTC124 FAQs: frequently asked questions about PTC124.

Hankard R, Mauras N, Hammond D, Haymond M, Darmaun D. Is glutamine a 'conditionally essential' amino acid in Duchenne muscular dystrophy? Clinical nutrition (Edinburgh, Scotland). Dec 1999;18(6):365-369.

Hespel P, Op't Eijnde B, Van Leemputte M, Urso B, Greenhaff PL, Labarque V, . . . Richter EA. Oral creatine supplementation facilitates the rehabilitation of disuse atrophy and alters the expression of muscle myogenic factors in humans. The Journal of physiology. Oct 15 2001;536(Pt 2):625-633.

Hibaoui Y, Reutenauer-Patte J, Patthey-Vuadens O, et al. “Melatonin improves muscle function of the dystrophic mdx5Cv mouse, a model for Duchenne muscular dystrophy.” J Pineal Res 51 (2011): 163-171.

Hori YS, Kuno A, Hosoda R, et al. “Resveratrol ameliorates muscular pathology in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy.” J Pharmacol Exp Ther 338(2011): 784-794.

Kawai H. [Miyoshi distal muscular dystrophy (Miyoshi myopathy)]. Brain and nerve = Shinkei kenkyu no shinpo. Feb 2011;63(2):147-156.

Kazuki Y, Hiratsuka M, Takiguchi M, et al. "Complete genetic correction of IPD cells from Duchenne Muscular Dystrophy." Mol Ther 18 (2010): 386-393.

Kinali M, Manzur AY, and Muntoni F. "Recent developments in the management of Duchenne Muscular Dystrophy." Paediatrics and Child Health 18 (2007): 22-26.

Klopstock T, Querner V, Schmidt F, Gekeler F, Walter M, Hartard M, . . . Muller-Felber W. A placebo-controlled crossover trial of creatine in mitochondrial diseases. Neurology. Dec 12 2000;55(11):1748-1751.

Krivickas LS, Walsh R, and Amato AA. "Single muscle fiber contractile properties in adults with muscular dystrophy treated with MYO-029." Muscle Nerve 39 (2009): 3-9.

Kumar A, Yamauchi J, Girgenrath T, et al. "Muscle-specific expression of insulin-like growth factor 1 improves outcome in LAMA2y-w mice, a model for congenital muscular dystrophy type 1a." Hum Mol Genet 20 (2011): 2333-2343.

Kuno A, Hori YS, Hosoda R, Tanno M, Miura T, Shimamoto K, Horio Y. Resveratrol improves cardiomyopathy in dystrophin-deficient mice through SIRT1 protein-mediated modulation of p300 protein. The Journal of biological chemistry. Feb 22 2013;288(8):5963-5972.

Kurreck J "Antisense technologies. Improvement through novel chemical modifications." European Journal of Biochemistry 270, no. 8 (2003): 1628-1644.

Kyriacou K, Kassianides B, Hadjisavvas A, Middleton L, Kyriakides T. The role of electron microscopy in the diagnosis of nonneoplastic muscle diseases. Ultrastructural pathology. May-Jun 1997;21(3):243-252.

Le Borgne F, Guyot S, Logerot M, et al. “Exploration of lipid metabolism in relation with plasma membrane properties of Duchenne muscular dystrophy cells: influence of L-carnitine.” PloS One 7 (2012): e49346.

Letellier G, Mok E, Alberti C, et al. "Effect of glutamine on glucose metabolism in children with Duchenne Muscular Dystrophy." Clin Nutr [Epub ahead of print, Sep 14 2012].

Littarru GP and Tiano L "Clinical aspects of coenzyme Q10: an update." Nutrition 26 (2010): 250-254.

Logigian EL, Martens WB, Moxley RT 4th, et al. "Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1." Neurology 74 (2010): 1441-1448.

Louis M, Lebacq J, Poortmans JR, Belpaire-Dethiou MC, Devogelaer JP, Van Hecke P, . . . Francaux M. Beneficial effects of creatine supplementation in dystrophic patients. Muscle & nerve. May 2003;27(5):604-610.

Malik V, Rodino-Klapac LR, and Mendell JR "Emerging drugs for Duchenne Muscular Dystrophy." Expert Opin Emerging Drugs 17 (2012): 261-277.

Manzur AY and Muntoni F "Diagnosis and new treatments in Muscular Dystrophies." Postgraduate Medical Journal 85 (2009): 622-630.

Markham LW, Kinnett K, Wong BL, et al. "Corticosteroid treatment retards development of ventricular dysfunction in Duchenne Muscular Dystrophy." Neuromuscul Disord 18 (2008): 365-370.

MayoClinic. "Muscular Dystrophy." (2012).

Meola G and Moxley RT 3rd. "Myotonic Dystrophy Type 2 and Related Myotonic Disorders." J Neurol 251 (2004): 1173-1182.

Mercuri E and Muntoni F. "The Ever-Expanding Spectrum of Congenital Muscular Dystrophies." Ann Neurol 72 (2012): 9-17.

Mercuri E, Muntoni F. Muscular dystrophies. Lancet. Feb 22 2013.

Millay DP, Goonasekera SA, Sargent MA, et al. "Calcium influx is sufficient to induce muscular dystrophy through a TRPC-dependent mechanism." Proc Natl Acad Sci U S A 106 (2009): 19023-19028.

Miyazaki T, Honda A, Ikegami T, Matsuzaki Y. The role of taurine on skeletal muscle cell differentiation. Advances in experimental medicine and biology. 2013;776:321-328.

Moghadaszadeh B, Petit N, Jaillard C, et al. “Mutations in SEPN1 cause congenital muscular dystrophy with spinal rigidity and restrictive respiratory syndrome.” Nat Genet 29 (2001): 17-18.

Mok E, Constantin B, Favreau F, et al. "L-Glutamine administration reduces oxidized glutathione and map kinase signaling in dystrophic muscle of mdx mice." Pediatr Res 63 (2008): 268-273.

Mok E, Eleouet-Da Violante C, et al. "Oral glutamine and amino acid supplementation inhibit whole-body protein degradation in children with Duchenne Muscular Dystrophy." Am J Clin Nutr 83 (2006): 823-828.

Morrison LA "Dystrophinopathies." Handb Clin Neurol 101 (2011): 11-39.

Muir LA and Chamberlain JS "Emerging strategies for cell and gene therapy of the muscular dystrophies." Expert Rev Mol Med 11 (2009): e18.

Nakae Y, Hirasaka K, Goto J, et al. “Subcutaneous injection, from birth, of epigallocatechin-3-gallate, a component of green tea, limits the onset of muscular dystrophy in mdx mice: a quantitative histological, immunohistochemical and electrophysiological study.” Histochem Cell Biol 129 (2008): 489-501.

Nelson SF, Crosbie RH, Miceli MC, et al. "Emerging genetic therapies to treat Duchenne Muscular Dystrophy." Curr Opin Neurol 22 (2009): 532-538.

NHGRI. National Human Genome Research Institute; National Institutes of Health. Learning about myotonic Dystrophy. Available at: Accessed 5/20/2013. 2012.

NIH Genetics Home Reference (2013A). Myotonic dystrophy. Available at: Last accessed February 4, 2013.

NIH Genetics Home Reference (2013B) Oculopharyngeal muscular dystrophy. Available at: Last accessed February 2, 2013.

NIH. Muscular dystrophy. Available at: Last accessed December 23, 2012.

NINDS. "Muscular Dystrophy: hope through research." (2011)

Otto RK, Ferguson MR, and Friedman SD. "Cardiac MRI in muscular dystrophy: an overview and future directions." Phys Med Rehabil Clin N Am 23 (2012): 123-132, xi-xii.

Pane M, Messina S, Bruno C, D'Amico A, Villanova M, Brancalion B, . . . Mercuri E. Duchenne muscular dystrophy and epilepsy. Neuromuscular disorders : NMD. Apr 2013;23(4):313-315.

ParentProjectMD. Parent Project Muscular Dystrophy. About Dystrophin and Utrophin. Available at: Accessed 5/24/2013. 2012.

Park IH, Arora N, Huo H, et al. "Disease-specific induced pluripotent stem cells." Cell 134 (2008): 877-886.

Passaquin AC, Renard M, Kay L, et al. "Creatine supplementation reduces skeletal muscle degeneration and enhances mitochondrial function in mdx mice." Neuromuscul Disord 12 (2002): 174-182.

Paunescu LA, Ko TH, Duker JS, et al. "Idiopathic juxtafoveal retinal telangiectasis: new findings by ultrahigh-resolution optical coherence tomography." Ophthalmology 113 (2006): 48-57.

Payan CA, Hogrel JY, Hammouda EH, et al. "Periodic salbutamol in facioscapulohumeral muscular dystrophy: a randomized controlled trial." Arch Phys Med Rehabil 90 (2009): 1094-1101.

Payne ET, Yasuda N, Bourgeois JM, et al. "Nutritional therapy improves function and complements corticosteroid intervention in mdx mice." Muscle Nerve 33 (2006): 66-77.

Pearlman, Jared P, and Fielding RA. "Creatine monohydrate as a therapeutic aid in muscular dystrophy." Nutrition Reviews 64 (2006): 80-88.

Persky AM, Brazeau GA. Clinical pharmacology of the dietary supplement creatine monohydrate. Pharmacological reviews. Jun 2001;53(2):161-176.

Pilgram GS, Potikanond S, Baines RA, et al. "The roles of the dystrophin-associated glycoprotein complex at the synapse." Mol Neurobiol 41 (2010): 1-21.

Pistoni M, Ghigna C, and Gabellini D. "Alternative splicing and muscular dystrophy." RNA Biology 7 (2010): 441-452.

Politano L and Nigro G "Treatment of dystrophinopathic cardiomyopathy: review of the literature and personal results." Acta Myologica XXXI (2012): 24-30.

Potgieter M, Pretorius E, Van der Merwe CF, et al. "Histological assessment of SJL/J mice treated with the antioxidants coenzyme Q10 and resveratrol." Micron 42 (2011): 275-282.

Price FD, Kuroda K, and Rudnicki MA. "Stem cell based therapies to treat muscular dystrophy." Biochim Biophys Acta 1772 (2007): 272-283.

PubMed Health. Duchenne muscular dystrophy. Available at: Last accessed February 4, 2013.

Radley HG, De Luca A, Lynch GS, et al. "Duchenne Muscular Dystrophy: focus on pharmaceutical and nutritional interventions." Int J Biochem Cell Biol 39 (2007): 469-477.

Ramaswamy KS, Palmer ML, van der Meulen JH, et al. "Lateral transmission of force is impaired in skeletal muscles of dystrophic mice and very old rats." J Physiol 589 (2011): 1195-1208.

Rederstorff M, Krol A, and Lescure A. “Understanding the importance of selenium and selenoproteins in muscle function.” Cell Mol Life Scie 63 (2006): 52-59.

Reed UC "Congenital Muscular Dystrophy. Part I: A review of phenotypical and diagnostic aspects." Arq Neuropsiquiatr 67 (2009A): 144-168.

Reed UC. “Congenital muscular dystrophy. Part II: a review of pathogenesis and therapeutic perspectives.” Arq Neuropsiquiatr 67 (2009B):343-362.

Relaix F, Zammit PS "Satellite cells are essential for skeletal muscle regeneration: the cell on the edge returns centre stage." Development 139 (2012): 2845-2856.

Rocha CT, Hoffman EP “Limb-girdle and congenital muscular dystrophies: current diagnostics, management, and emerging technologies.” Curr Neurol Neurosci Rep 10 (2010): 267-276.

Romeo V "Myotonic Dystrophy Type I or Steinert Disease." In: Neurodegenerative Diseases, (Shamim I. Ahmad, Ed.), Chapter 18 (2012): 239-257.

Rutter MM, Collins J, Rose SR, et al. "Growth hormone treatment in boys with duchenne muscular dystrophy and glucocorticoid-induced growth failure." Neuromuscul Disord 22 (2012): 1046-1056.

Sahenk Z and Mendell JR "The muscular dystrophies: distinct pathogenic mechanisms invite novel therapeutic approaches." Curr Rheumatol Rep 13 (2011): 199-207.

Schara U and Schoser BG "Myotonic dystrophies type 1 and 2: a summary on current aspects." Semin Pediatr Neurol 13 (2006): 71-79.

Scionti I, Greco F, Ricci G, Govi M, Arashiro P, Vercelli L, . . . Tupler R. Large-scale population analysis challenges the current criteria for the molecular diagnosis of fascioscapulohumeral muscular dystrophy. American journal of human genetics. Apr 6 2012;90(4):628-635.

Siciliano G, Mancuso M, Tedeschi D, Manca ML, Renna MR, Lombardi V, . . . Murri L. Coenzyme Q10, exercise lactate and CTG trinucleotide expansion in myotonic dystrophy. Brain research bulletin. Oct-Nov 1 2001;56(3-4):405-410.

Silva LA, Silveira PC, Ronsani MM, Souza PS, Scheffer D, Vieira LC, . . . Pinho RA. Taurine supplementation decreases oxidative stress in skeletal muscle after eccentric exercise. Cell biochemistry and function. Jan-Feb 2011;29(1):43-49.

Simonds AK. “Respiratory complications of the muscular dystrophies.” Seminars in Respiratory and Critical Care Medicine 23 (2002) 231-238.

Sparks SE and Escolar DM. "Congenital Muscular Dystrophies." Handb Clin Neurol 101 (2011): 47-79.

Spence HJ, Dhillon AS, James M, et al. "Dystroglycan, a scaffold for the ERK-MAP kinase cascade." EMBO Rep 5 (2004): 484-489.

Spurney CF, Rocha CT, Henricson E, Florence J, Mayhew J, Gorni K, . . . Escolar DM. CINRG pilot trial of coenzyme Q10 in steroid-treated Duchenne muscular dystrophy. Muscle & nerve. Aug 2011;44(2):174-178.

Strober JB "Therapeutics in Duchenne Muscular Dystrophy." NeuroRX 3 (2006): 225-234.

Tarnopolsky MA "Creatine as a therapeutic strategy for myopathies." Amino Acids 40 (2011): 1397-1407.

Tawil R "Facioscapulohumeral Muscular Dystrophy." Neurotherapeutics 5 (Oct 2008): 601-606.

Tedeschi D, Lombardi V, Mancuso M, Martelli F, Sighieri C, Rocchi A, . . . Murri L. Potential involvement of ubiquinone in myotonic dystrophy pathophysiology: new diagnostic approaches for new rationale therapeutics. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2000;21(5 Suppl):S979-980.

Tidball JG and Wehling-Henricks M. “The role of free radicals in the pathophysiology of muscular dystrophy.” J Appl Physiol 102 (2007): 1677-1686.

Trollet C, Athanasopoulos T, Poplewell L, et al. "Gene therapy for muscular dystrophy: current progress and future prospects." Expert Opin Biol Ther 9 (2009): 849-866.

Vallese D, Yada E, Butler-Browne G, et al. "Cell-based therapies in skeletal muscle disease." In: Muscle Fundamental Biology and Mechanisms of Disease, Joseph Hill and Eric Olson (Eds.), 1053-1063, 2012.

van der Spuy WJ, Potgieter M, Pretorius E, et al. "Differential leukocyte counts of Sjl/J mice with dysferlinopathy treated with resveratrol and coenzyme Q10." Scand J Lab Anim Sci 37 (2010): 93-99.

Walter MC and Lochmüller C "Muscular dystrophies." Neurology and Clinical Neuroscience (2007): 1142-1167.

Walter MC, Lochmuller H, Reilich P, Klopstock T, Huber R, Hartard M, . . . Muller-Felber W. Creatine monohydrate in muscular dystrophies: A double-blind, placebo-controlled clinical study. Neurology. May 9 2000;54(9):1848-1850.

Wang Z, Chamberlain JS, Tapscott SJ, et al. "Gene therapy in large animal models of muscular dystrophy." ILAR J 50 (2009): 187-198.

Welch EM, Barton ER, Zhuo J, et al. "PTC124 targets genetic disorders caused by nonsense mutations." Nature 447 (2007): 87-91.

Whitehead NP, Pham C, Gervasio OL, Allen DG. N-Acetylcysteine ameliorates skeletal muscle pathophysiology in mdx mice. The Journal of physiology. Apr 1 2008;586(7):2003-2014.